Format
Sort by

Send to

Choose Destination

Search results

Items: 3

  • Filters activated: Cancer. Clear all to show 3 items.
1.

UNBS5162 inhibits the proliferation of esophageal cancer squamous cells via the PI3K/AKT signaling pathway.

He D, Zhang S.

Mol Med Rep. 2018 Jan;17(1):549-555. doi: 10.3892/mmr.2017.7893. Epub 2017 Oct 26.

PMID:
29115622
2.

Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma.

Mahadevan D, Northfelt DW, Chalasani P, Rensvold D, Kurtin S, Von Hoff DD, Borad MJ, Tibes R.

Int J Clin Oncol. 2013 Oct;18(5):934-41. doi: 10.1007/s10147-012-0475-8. Epub 2012 Oct 11.

3.

UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.

Mijatovic T, Mahieu T, Bruyère C, De Nève N, Dewelle J, Simon G, Dehoux MJ, van der Aar E, Haibe-Kains B, Bontempi G, Decaestecker C, Van Quaquebeke E, Darro F, Kiss R.

Neoplasia. 2008 Jun;10(6):573-86.

Supplemental Content

Loading ...
Support Center